Last month’s GMP Regulatory Intelligence Newsletter scans consisted mostly of just the bare essentials since I’ve been on vacation in Washington state doing a LOT of wonderful hiking with very little connectivity. This month will be back to normal…without the stunning scenery and hiking.
Happy Reading,
Barbara
To access the latest scans discussed here, please log in to the GMP Regulatory Intelligence Newsletter site.
Laws, Regulations, Guidance, and Concept Papers
- FDA published a variety of guidance documents in the areas of quality, generics, combination products, and general administrative requirements.
- Guidance was published by CDSCO, ICH, WHO, EMA, TGA, as well as Russia (which addressed data integrity).
- Non-guidance publications include the usual collection from MHRA, FDA, EMA, WHO, ICH, and TGA.
- The EMA annual report for 2017 from the GDMP Inspectorate is worth glancing thru for the graphics alone.
Enforcement
- FDA published 10 warning letters for drug product sites + 1 GLP site + 1 device firm. Of those issued to drug sites:
- 4 of those were OTC (and continue FDA’s focus on this market segment)
- 1 manufactures homeopathic products
- 1 manufactures solid oral drug products
- Some recalls, a variety of import alerts (including refusal of FDA inspections), and 1 safety alert.
- We are going to continue to see recalls of Valsartan products for a while as additional products are identified as being contaminated.